ablecraig's blog

Bio-layer interferometry is a label-free, real-time, and high-throughput technique used for studying biomolecular interactions. It leverages the principle of bio-layer interferometry, where light waves interfere with each other to create an optical signal. In the case of BLI, a biosensor tip is coated with a biorecognition molecule, such as a protein or a DNA probe. The biosensor tip is then placed in a sample containing the target analyte, and changes in the optical signal are measured as the analyte binds to the biorecognition molecule. It allows researchers to measure the binding kinetics and affinities of a variety of biomolecular interactions, including protein-protein, protein-small molecule, protein-DNA, and protein-lipid interactions.

With the BLI platform, CD BioSciences can provide testing services for a variety of biomolecular and comprehensive analysis services. From the detection of protein, nucleic acid, and antibody to protein-DNA interactionsand many other molecular interaction assays, their BLI technology solutions can cover research needs in the field of drug discovery and development.

CD BioSciences’ BLI platform offers several advantages over traditional BIA techniques, such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). This platform is able to measure biomolecular interactions in real time, enabling researchers to study complex binding mechanisms and determine the rate constants of association and dissociation. Additionally, BLI requires relatively low sample volumes, making it suitable for studying precious or limited samples. Moreover, the BLI platform also offers flexibility in experimental design. It allows for multiplexing, where several analytes or reference compounds can be immobilized on different biosensor tips and measured simultaneously. This enables high-throughput screening of compound libraries or the simultaneous analysis of multiple interactions in complex biological systems.

“With the launch of ourbio-layer interferometry platform, we aim to help our clients accelerate their drug discovery and development processes,” said a spokesperson for CD BioSciences. “By providing them with access to advanced technology and expertise, we enable them to make informed decisions and bring their drug candidates to market faster.”

With the increasing prevalence of neurological diseases, such as Alzheimer’s, Parkinson’s, and multiple sclerosis, the need for comprehensive and precise analysis methods has become more urgent than ever. CD BioSciences has risen to this challenge by employing advanced biophysical analysis tools, enabling scientists to delve into the complexity of neural mechanisms with superior accuracy and depth.

Through strategic partnerships with top-tier research institutions and the dedication of its team, CD BioSciences has developed an impressive suite of biophysical platforms tailored specifically to neuroscience research. By integrating innovative technologies with cutting-edge algorithms, they have unlocked new perspectives and avenues for exploration, driving notable progress in the field.

One of CD BioSciences’ most significant techniques is its whole-brain imaging based on biophysical technology. By utilizing state-of-the-art microscopy technologies, researchers are now able to visualize and analyze neuronal connections at an unprecedented resolution, which not only deepens the understanding of neural circuits but also offers new opportunities for the development of targeted therapeutic interventions.

Furthermore, CD BioSciences’ biophysical analysis methods have been pivotal in uncovering the underlying biological mechanisms behind various neurological disorders. Through the application of its proprietary software algorithms, the company can help researchers determine the molecular interactions, structural changes, and protein dynamics associated with these disorders.